Joan Montero

Joan Montero

UNVERIFIED PROFILE

Are you Joan Montero?   Register this Author

Register author
Joan Montero

Joan Montero

Publications by authors named "Joan Montero"

Are you Joan Montero?   Register this Author

22Publications

624Reads

11Profile Views

A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies.

Clin Cancer Res 2020 Feb 16;26(4):761-763. Epub 2019 Dec 16.

Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-3670DOI Listing
February 2020

Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies.

Nat Commun 2019 11 14;10(1):5157. Epub 2019 Nov 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, 02115, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-12477-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856172PMC
November 2019

Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.

Proc Natl Acad Sci U S A 2019 01 31;116(3):1027-1032. Epub 2018 Dec 31.

Program in Virology, Graduate School of Arts and Sciences, Harvard University, Cambridge, MA 02138;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1818798116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338866PMC
January 2019

The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading.

Redox Biol 2018 04 14;14:164-177. Epub 2017 Sep 14.

Department of Cell Death and Proliferation, Instituto de Investigaciones Biomédicas de Barcelona, Consejo Superior de Investigaciones Científicas, 08036 Barcelona, Spain; Liver Unit and Hospital Clínic i Provincial, IDIBAPS, and Centro de Investigación Biomédica en Red (CIBERehd), Spain; Southern California Research Center for ALPD and Cirrhosis, Los Angeles, CA, USA; University of Southern California Research Center for Liver Diseases, Keck School of Medicine, USC, Los Angeles, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.redox.2017.08.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609874PMC
April 2018

Why do BCL-2 inhibitors work and where should we use them in the clinic?

Cell Death Differ 2018 01 27;25(1):56-64. Epub 2017 Oct 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cdd.2017.183DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729538PMC
January 2018

Why do BCL-2 inhibitors work and where should we use them in the clinic?

Cell Death Differ 2018 Jan 27;25(1):56-64. Epub 2017 Oct 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 02215, USA, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cdd.2017.183DOI Listing
January 2018

Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis.

Sci Transl Med 2017 Dec;9(420)

Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aal3765DOI Listing
December 2017

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 07 11;30(1):183. Epub 2016 Jul 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.008DOI Listing
July 2016

Dynamic BH3 profiling-poking cancer cells with a stick.

Mol Cell Oncol 2016 May 10;3(3):e1040144. Epub 2016 Mar 10.

Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2015.1040144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909438PMC
May 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 04;29(4):574-586

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177991PMC
April 2016

BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.

Mol Cell 2013 Sep;51(6):751-65

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2013.08.048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164233PMC
September 2013

Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death.

Biochim Biophys Acta 2010 Jun-Jul;1797(6-7):1217-24. Epub 2010 Feb 11.

Liver Unit and Centro de Investigaciones Biomédicas Esther Koplowitz, IMDiM, Hospital Clínic i Provincial and CIBEREHD, IDIBAPS, and Department of Cell Death and Proliferation, Instituto Investigaciones Biomédicas de Barcelona, Consejo Superior de Investigaciones Científicas, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbabio.2010.02.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889134PMC
January 2011

Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma.

Cancer Res 2008 Jul;68(13):5246-56

Liver Unit and Centro de Investigaciones Biomédicas Esther Koplowitz, IMDiM, Hospital Clínic i Provincial, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-6161DOI Listing
July 2008